Printer Friendly

LIDAK PHARMACEUTICALS AND RIBI IMMUNOCHEM RESEARCH COLLABORATE ON POTENTIAL CANCER VACCINE

 LA JOLLA, Calif., Aug. 24 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) announced today that it has entered into an agreement with Ribi Immunochem Research, Inc. (NASDAQ: RIBI) under which Ribi has granted LIDAK a license to use Ribi's melanoma cell lines in the clinical development of LIDAK's Large Multivalent Immunogen (LMI) technology. In return, LIDAK has granted Ribi an option for an exclusive license to use the LMI technology with Ribi's melanoma cell lines for the treatment of melanoma, should preclinical and human clinical development of the technology prove successful. This agreement does not restrict LIDAK from using their LMI technology for treatment of melanoma using melanoma antigens from other sources.
 Ribi has an exclusive license to the melanoma cell lines from the University of Southern California. The cell lines are used in the manufacture of Ribi's MELACINE melanoma theraccine, which is currently in two Phase III human clinical studies for the treatment of melanoma. If successful, the LIDAK LMI technology, used with Ribi-USC melanoma cell lines, may lead to the next generation of cancer vaccines.
 LMI may have application in improving human responses to various cancer and viral antigens. LMI technology incorporates antigenic material on cell-sized microspheres, creating a "virtual" cancer cell or virus that is non-virulent and is relatively large and well-recognized by the immune system compared to individual pieces of antigenic material. Results of pre-clinical testing of LMI in a mouse tumor model indicate that LMI stimulated a protective immune response, including a satisfactory cellular response. A cellular (or cell-mediated) immune response has been found to be more effective against cancer and viral diseases than a humoral or antibody-based response.
 "This agreement facilitates our ability to move into human clinical trials to assess the efficacy and safety of the LMI technology in patients with malignant melanoma," said David M. Katz, president and chief executive officer of LIDAK.
 LIDAK Pharmaceuticals is developing therapeutic products against virally caused diseases, inflammatory disorders and cancer. The company's initial focus is on the commercialization of LIDAKOL as a treatment for herpes and other indications. The company is also developing its Large Multivalent Immunogen technology for potential new therapies against cancer and viral diseases.
 -0- 8/24/93
 /CONTACT: Michael H. Lorber, vice president and CFO of LIDAK Pharmaceuticals, 619-558-0364, or Fern Lazar of Dewe Rogerson Inc., 212-688-6840/
 (LDAKA RIBI)


CO: LIDAK Pharmaceuticals; Ribi Immunochem Research, Inc. ST: California IN: MTC SU: LIC

PS-TS -- NY010 -- 5356 08/24/93 09:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1993
Words:408
Previous Article:MIDWESCO REPORTS SECOND QUARTER, SIX MONTHS EARNINGS GAINS
Next Article:PRIDE PETROLEUM SERVICES APPOINTS JAMES W. ALLEN TO HEAD LATIN AMERICAN OPERATIONS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters